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Abstract  
Background: Prenatal exposure to environmental adversities, including maternal 
overweight/obesity, diabetes/hypertensive or mood/anxiety disorders, increases the risk for adverse 
neurodevelopmental outcomes in children. However, the underlying biological mechanisms remain 
elusive. We tested whether maternal antenatal inflammation associated with the number of 
neurodevelopmental delay areas in children and mediated the association between exposure to any 
prenatal environmental adversity and child neurodevelopmental delay. 
Methods: Mother-child dyads (N=418) from the Prediction and Prevention of Preeclampsia and 
Intrauterine Growth Restriction (PREDO) study were followed-up to 10.8 years. We analyzed 
maternal plasma high-sensitivity C-reactive-protein (hsCRP) and glycoprotein acetyls at three 
consecutive antenatal time points, extracted data on maternal body mass index in early pregnancy, 
and diabetes/hypertensive disorders in pregnancy from medical records, and mood/anxiety disorders 
until childbirth from the Care Register for Health Care (HILMO). To estimate the number of 
neurodevelopmental delay areas in children across cognitive, motor and social functioning, we 
pooled data from HILMO on psychological development disorders with mother-reported Ages and 
Stages Questionnaire data on developmental milestones. 
Results: Higher levels of maternal hsCRP and glycoprotein acetyls at and across all three antenatal 
time points were associated with 1.30 to 2.36-fold (p-values<0.02) increased relative risk for higher 
number of areas of child neurodevelopmental delay. Higher maternal inflammation across the three 
time points also mediated the effect of any prenatal environmental adversity on child 
neurodevelopmental delay. 
Conclusions: Higher levels of maternal inflammation, especially when persisting throughout 
pregnancy, increase child’s risk of neurodevelopmental delay and mediate the effect of prenatal 
environmental adversity on child neurodevelopmental delay. 
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Introduction  
The Developmental Origins of Health and Disease (DOHaD) framework suggests that individual 
neurodevelopmental trajectories are shaped by environmental influences during prenatal life(1).  
Indeed, a number of studies have reported that prenatal exposure to environmental adversities, 
including maternal overweight/obesity(2-6), diabetes and hypertensive disorders(2, 7, 8), depression 
and anxiety(9, 10), increases child risk of neurodevelopmental delay, poorer cognition and mental 
disorders. As these maternal conditions associate with a quantifiable inflammatory response in 
pregnancy(11, 12), it has been proposed that maternal inflammation may be among the mechanisms 
linking prenatal environmental adversities with child neurodevelopmental outcomes(13). 
Studies addressing this question have produced mixed findings. They have shown that higher 
maternal immunoglobulin antibodies (e.g., toxoplasma immunoglobulin antibody), C-reactive 
protein (CRP) or pro- and anti-inflammatory cytokines, interleukin-4 (IL-4), IL-5, IL-6, IL-8, 
and/or tumor necrosis factor-alpha (TNF-α) during pregnancy are associated with offspring  
neurodevelopmental delay(14), impaired neurocognitive development(15-18), internalizing and 
externalizing problems(19), autism spectrum disorders (ASD)(14, 20, 21) and schizophrenia(22-
26). According to recent neuroimaging studies, higher maternal IL-6 during pregnancy is also 
associated with alterations in newborn structural and functional brain connectivity and development 
in infancy across various brain regions and networks, and these alterations may mediate the 
associations between IL-6 and lower impulse control, poorer working memory and cognition in 
children(16-18). However, some studies have reported that higher levels of these maternal 
inflammatory biomarkers are associated with higher cognitive abilities, lower risk of neurological 
abnormalities(15, 27, 28), lower risk of schizophrenia(25), major depression(29), and ASD(30) in 
the children, and some others have reported that these maternal inflammatory biomarkers are not 
associated with risk of ASD(23), schizophrenia(31) or bipolar disorder(32, 33) in children. 
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While the mixed findings may result from methodological differences between the studies, 
including variation in the studied set of inflammatory biomarkers and small sample sizes, they may 
also reflect reliance on a single measurement point(14, 21, 22, 26, 28, 34, 35) and variation in the 
stage of pregnancy when inflammatory biomarkers were measured. This is critical as pregnancy 
triggers a marked inflammatory response showing large inter-individual differences(36). Hence, it 
remains unknown if there exists a critical window of vulnerability during pregnancy, and if 
fluctuations in maternal inflammatory biomarkers during pregnancy or persistently high levels are 
more critical for in utero neurodevelopment than the level of inflammation at one single point 
during pregnancy. To the best of our knowledge, previous studies have not addressed these 
possibilities even if inflammatory biomarkers were measured more than once during pregnancy(16-
18, 20, 29, 31-33). 
Furthermore, we are not aware of any studies testing if maternal inflammatory biomarkers mediate 
the associations between prenatal environmental adversities and child neurodevelopment. One study 
has demonstrated that lower maternal IL-8, but not maternal IL-β1, IL-6, IL-10 or TNF-α, measured 
at 32 gestational weeks, mediated the association between maternal socioeconomic disadvantage 
during pregnancy and higher risk of child neurological abnormalities(27). 
We tested if maternal high-sensitivity CRP (hsCRP) and glycoprotein acetyls, measured at three 
consecutive antenatal timepoints, were associated with higher risk of neurodevelopmental delay in 
their children.  We also tested if the predictive significance of hsCRP and glycoprotein acetyls 
varied according to the stage of pregnancy and if any fluctuations or persistently high levels in these 
inflammatory biomarkers predicted child risk of neurodevelopmental delay. Furthermore, we tested 
if maternal hsCRP and glycoprotein acetyls mediated the associations between exposure to any 
prenatal environmental adversity (maternal overweight/obesity, diabetes, hypertensive, mood and/or 
anxiety disorders diagnosed before and during pregnancy) and child neurodevelopmental delay and 
if these associations varied by child sex, since there is evidence that the associations between 
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prenatal environmental adversities and child neurodevelopmental outcomes may be sex-specific(37, 
38). We focused on hsCRP and glycoprotein acetyls since both of these inflammatory biomarkers 
have long half-lives, indicate systemic, low-grade chronic inflammation(39) and are elevated in 
women during pregnancy(40). HsCRP is widely used in clinical practice and is among the most 
extensively used inflammatory biomarkers in research. High hsCRP is linked with depression(41, 
42) and cardiovascular mortality(43). Glycoprotein acetyls is a novel systemic inflammatory 
biomarker. It represents a composite signal of changes in multiple circulating glycoproteins and is 
suggestive of a prolonged low-grade inflammatory state(39). Both hsCRP and glycoprotein have 
been linked with overweight/obesity, chronic hypertension, preeclampsia, gestational diabetes and 
depression during pregnancy(44). 
 
Methods and Materials 
Sample 
The participants come from the Prediction and Prevention of Pre-eclampsia and Intrauterine Growth 
Restriction (PREDO) study(45). We enrolled 1,079 pregnant women to the clinical subsample: 969 
had one or more, and 110 had none of the known risk factors for pre-eclampsia and intrauterine 
growth restriction (IUGR). The women were recruited when they arrived for their first ultrasound 
screening at 12-14 gestational weeks from 10 hospitals in Southern and Eastern Finland.  
Of the 1,079 women, 420 donated blood at up to three antenatal time points. Economic constraints 
restricted blood sampling to the three largest study hospitals. The samples were taken at median 
(interquartile range) 13.0(12.6-13.4), 19.3(19.0-19.7), and 27.0(26.6-27.6) gestational weeks. Of the 
420 women, 379(90.2%) provided blood samples at all three consecutive timepoints, 39(9.3%) at 
two timepoints, and 2(0.5%) at one timepoint. Of these women, 418(99.5%) had data available from 
Care Register for Health Care (HILMO) on child psychological development disorder diagnoses up 
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to child age of 7.1-10.8 years. These data were enriched by mother-reports of child developmental 
milestones available for 195(46.7% of the 418 women with blood samples and child diagnoses data) 
children at 2.3-5.7 years of age.  
Women providing blood samples were younger (32.6 vs. 33.5 years, p=0.007) and less likely to be 
obese (body mass index [BMI]>30 kg/m2) (29.4% vs. 39.3%, p=0.003) than women who did not. 
The groups with and without blood samples did not differ in other study variables and those with 
and without mother-reports on child developmental milestones did not differ in any study variables 
(p>0.06).  
All participants signed informed consents. The PREDO study protocol was approved by ethics 
committees of the Helsinki and Uusimaa Hospital District and aligns with The Code of Ethics of the 
World Medical Association (Declaration of Helsinki). 
Maternal inflammatory biomarkers 
Venous blood samples were drawn from antecubital vein between 7-9 AM, after  at least a 10 hour 
fast with plasma  separated immediately and stored at -80°C.HsCRP (mg/L)  was analyzed with a 
Beckman-Coulter CRP immunoturbidometric assay and Olympus AU680 analyzer (Beckman 
Coulter Inc., CA, USA)(intra-assay variation  was between 2.6 % (n=10, mean 1.20 mg/L) and 0.7 
% (n=10, mean 65 mg/L) and inter-assay variations were 3.5 % (n=30, mean 1.07 mgLl), 1.2 % 
(n=30, mean 11.5 mg/L) and 2.9% (n=30, mean 73 mg/L). The limit of detection of the hsCRP 
method is 0.02 mg/L and the functional sensitivity was better than 0.1 mg/L. Glycoprotein acetyls 
(mmol/L) were analyzed using a high-throughput nuclear magnetic resonance (NMR) metabolomics 
platform (1HNMR spectra, Nightingale Ltd.; Espoo, Finland)(46). 
Child neurodevelopmental delay 
Psychological development disorders were identified from HILMO since birth until 31 December 
2016. HILMO includes all in-patient  (since 1969) and outpatient treatments (since 1998) by 
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physicians in public specialized-care, and covers psychiatric diagnoses well  (47). Diagnoses are 
based on the International Classification of Diseases, Tenth Revision (ICD-10), identifying 
developmental disorders of speech and language (F80), scholastic skills (F81) and motor function 
(F82), mixed specific developmental disorders (F83), and ASD (F84). 
In addition to the diagnoses, the children were considered to display neurodevelopmental delay if 
their score on The Ages and Stages Questionnaires (ASQ) Third edition was ≤-2SD for age(48). 
ASQ measures communication, problem solving, gross motor, fine motor and personal/social skills 
and comprises 30 age-appropriate items scored “10” if the child can master the skill,  “5” if the skill 
is emerging/occasional, and “0” if the child cannot perform the skill(48-50). Age-appropriate ASQ 
means and SDs were derived from the reference population of the children participating in the 
PREDO study (2). The groups comprised children aged 25.5-28.5 (n=2), 28.5-31.5 (n=21), 31.5-
34.5 (n=27), 34.5-39.0 (n=23), 39.0-45.0 (n=24), 45.0-51.0 (n=33), 51.0-57.0 (n=30), and 57.0-66.0 
(n= 24) months. We allowed 30% deviation from the questionnaire-specific age translating into 3 
weeks in the youngest and 2.7 months in the oldest age group.  
The ASQ (≤-2SD for age on any ASQ domain) correctly identified psychological development 
disorder status for 85.7% (430/502; 502 of 1079 children in clinical subsample had ASQ data; 
chance-corrected first-order agreement coefficient [AC1](51)=0.82, 95%Confidence Interval 
[95%CI]( 0.78, 0.86) and 88.7% (173/195; 195 of the 418 children in our analytic sample had ASQ 
data; AC1=0.85, 95%CI (0.79, 0.92) of children in the clinical and analytics subsample of the 
current study, respectively (Supplemental Figure 1). Any delay in ASQ also increased significantly 
the odds (odds ratio=[OR] 9.8, 95% CI 4.4, 21.4, p<0.0001, OR=11.5, 95% Confidence Interval 
[95% CI] 2.8, 46.6, p=0.0007) of any psychological development disorder diagnoses (F80-F84) in 
the clinical and the analytic subsample of the current study, respectively. 
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Using information from both HILMO and ASQ, and to increase statistical power, we created one 
broad outcome variable based on the number of areas in which the child displayed 
neurodevelopmental delay: (1) delay in cognitive development (F80, F81, F83 or scoring ≤-2SD for 
age on ASQ communication and/or problem solving skills; none of the children with F83 had 
specific motor development disorders; (2) delay in motor development (F82 or scoring ≤-2SD for 
age on ASQ fine motor and/or gross motor skills), (3) delay in social development (F84 or scoring 
≤-2SD for age on ASQ personal/social skills).  Hence, this variable captures delay in all three (3), 
delay in any two (2), delay in any one (1) and no delay in any area (0).  
Prenatal environmental adversity  
These data were derived from the Medical Birth Register (MBR), HILMO and medical records. 
Maternal diabetes and hypertensive disorders were extracted from the medical records and verified 
by an expert jury comprising two medical doctors and a research nurse with expertise in obstetrics 
and gynecology. 
Maternal early pregnancy overweight/obesity was defined as BMI ≥25 kg/m2 verified by 
measurement conducted at first antenatal clinic visit at a mean 8.5 (SD=1.5) gestational weeks. 
Diabetes included type 1 diabetes and gestational diabetes (fasting, 1 or 2 h plasma glucose during a 
75 g oral glucose tolerance test ≥5.1, 10.0, or 8.5 mmol/L that emerged or was first identified during 
pregnancy). Hypertensive disorders included chronic hypertension (systolic/diastolic blood pressure 
≥140/90 mmHg present pre-pregnancy or diagnosed before 20th week of gestation, gestational 
hypertension (systolic/diastolic blood pressure ≥140/90 mmHg on ≥2 occasions at least 4 h apart in 
a woman who was normotensive before 20th week of gestation) and preeclampsia (systolic/diastolic 
blood pressure ≥140/90 mmHg on ≥2 occasions at least 4 h apart in a women who was 
normotensive before 20th week of gestation with proteinuria ≥300 mg/24 h). Maternal mood (ICD-
10 since 1996: F3; Diagnostic and Statistical Manual for Mental Disorders, Third Revision [DSM-
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III-R] between 1987-1995: 296, 3004A, 3011D) and anxiety/neurotic disorder (ICD-10 since 1996: 
F4; DSM-III-R: 3000-3003, 3006-3009, 3078A, 309) diagnoses were identified since 1987 until 
childbirth.   
Because of high comorbidity of these maternal conditions (Supplemental Table 1) we combined 
them into one composite variable of any prenatal environmental adversity.  
Covariates and moderators 
Based on previous literature, the following variables were included as covariates: maternal age at 
childbirth (<40≥ years)(44), smoking during pregnancy (yes/no)(52), occupational status (manual 
laborer/junior or senior clerical/entrepreneur)(53, 54), education (basic/secondary vs. tertiary)(44) 
and alcohol use  (yes/no)(55). Child sex (girl/boys) and year of birth were used both as covariates 
and moderators, because the associations between prenatal environmental adversities and child 
neurodevelopmental outcomes may be sex-specific(37, 38) and because of heterogeneity in follow-
up time. All covariates/moderators were derived from MBR except for maternal education and 
alcohol use, which were reported in early pregnancy. 
Statistical analyses 
Poisson regression tested if the relative risk (RR) for higher number of areas of neurodevelopmental 
delay was increased for children of women with higher levels of hsCRP and glycoprotein acetyls at 
the three sampling points.   
To test whether fluctuating or persistently elevated levels of maternal hsCRP and glycoprotein 
acetyls were associated with the number of areas of child neurodevelopmental delay, we first 
applied latent class analysis (LCA) to identify subgroups of women based on their antenatal 
inflammation profiles defined by both inflammatory biomarkers simultaneously. We compared two 
to six subgroups solutions using the following criteria for the most optimal solution(56): (1) Akaike 
Information Criterion, Bayesian Information Criterion  of goodness-of-fit, (2) reasonable 
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distribution of participants across subgroups (at least 10% of the sample), (3) high certainty of 
classification identified by posterior probabilities, and (4) clinical relevance. By using Poisson 
regression, we then examined if the number of areas of neurodevelopmental delay varied according 
to the maternal inflammation subgroups identified by the LCA.  
We explored whether maternal antenatal inflammation mediated the association between prenatal 
environmental adversity (maternal overweight/obesity, diabetes, hypertensive disorders, mood or 
anxiety disorders) and the number of child neurodevelopmental delay areas using the SPSS 
PROCESS macro with 5000 bootstrapped samples(57). As a mediator we used the inflammation 
subgroups identified by the LCA. Before testing mediation, we assured that the criteria for 
mediation were met: namely, that the predictor, mediator and outcome variables were interrelated. 
We made adjustments for all covariates, and tested moderation by child birth year and sex by 
introducing interaction terms of maternal antenatal inflammation x child birth year and maternal 
antenatal inflammation x child sex into the regression models. We also conducted sensitivity 
analyses assuring that the following conditions did not affect our findings: we excluded women 
diagnosed for the first time with mood (n=20) and/or anxiety/neurotic disorder (n=18) after 
childbirth, women diagnosed with acute infectious diseases within a month of any of the blood 
sampling points (n=13; these infections were identified with previously described ICD-10 
diagnostic codes)(58, 59), herpes simplex (n=3; A60 and B00), (none of the women had 
toxoplasmosis),  rheumatoid arthritis (n=2; M05, M06, M12, M45) or asthma (n=11; J45, J46) with 
diagnoses derived from HILMO. We also excluded women whose maximum hemoglobin value 
during pregnancy was < 105 g/L (n= 79)(60), as indicated by the patient case reports. Finally, we 
examined the associations with the number of areas of neurodevelopmental delay where we defined 
neurodevelopmental delay only based on HILMO data to make sure that mother-reports did not bias 
the results.  
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We normalized hsCRP with natural logarithm transformation and standardized hsCRP and 
glycoprotein acetyls (Mean=0, SD=1) to facilitate interpretation. RR and 95% CI show effect sizes; 
in the mediation analyses effect sizes are presented as regression coefficients and RR.  
Poisson regression was performed using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA); mediation 
analysis using SPSS-IBM (Software, v.24.0 SPSS); latent class analyses using Stata 15 (StataCorp. 
2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). 
Results 
Sample characteristics are in Table 1. HsCRP and glycoprotein acetyls were intercorrelated 
(Pearson r’s≥0.34, p<0.001) showing high rank-order stability across pregnancy (intraclass 
correlations≥0.76 and ≥0.72 for hsCRP and glycoprotein acetyls, respectively).  
 
Maternal inflammatory biomarkers at the three antenatal sampling points  
Table 2 shows that across all antenatal sampling points, higher maternal hsCRP and glycoprotein 
acetyl levels were associated with increased RR for higher number of child neurodevelopmental 
delay areas. These associations remained when adjusted for all covariates and prenatal 
environmental adversities, except for the associations with glycoprotein acetyls at the first and 
second blood sampling points, which were no longer significant when adjusted for prenatal 
environmental adversities (Table 2). Supplemental Table 2 shows the associations with the three 
specific neurodevelopmental areas as outcomes. 
Fluctuating and persistently high levels of maternal inflammatory biomarkers 
Figure 1 shows the most optimal LCA solution identified three subgroups of women who differed 
from each other in their hsCRP and glycoprotein acetyl levels. The inflammatory biomarkers 
showed high stability and lack of fluctuation across pregnancy in each group. The groups showed 
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consistently low (n=71[17%]), moderate (n=181[43.3%]) and high (n=166[39.7%]) levels of both 
hsCRP and glycoprotein acetyls across pregnancy. Supplemental Table 3 presents the LCA 
selection criteria for the 2-6 subgroups solutions.  
Child risk of higher number of neurodevelopmental delay areas increased linearly across maternal 
groups with low, moderate and high levels of antenatal inflammation (RR=2.36, 95% CI 1.57, 3.55, 
p<0.001). These associations remained when adjusted for covariates and prenatal environmental 
adversities (p-values <0.002). 
We also compared if glycoprotein acetyls added to the risk prediction of child neurodevelopmental 
delay in comparison to hsCRP alone. Before proceeding to this comparison, we identified the most 
optimal LCA solution based on hsCRP alone. LCA identified three groups of women with 
consistently low, moderate and high hsCRP levels (Supplemental Table 4). Child risk for higher 
number of neurodevelopmental delay areas increased significantly according to maternal hsCRP 
groups (RR=1.83, 95% CI 1.24, 2.70, p<0.001). Using Likelihood-Ratio-Test, we then compared 
goodness-of-fit of the following two nested models: the first, full model included the three-group 
LCA solution based on hsCRP and glycoprotein acetyls and the three-group LCA solution based on 
hsCRP, and the second, restricted model, included the three-group LCA solution based on hsCRP 
alone. Goodness-of-fit of the full model was better (deviance=278.39) than the restricted model 
(deviance=288.50) (Likelihood-Ratio-Test p<0.001). 
Moderation and mediation analyses 
None of the associations were moderated by child sex or birth year (p-values > 0.06; data not 
shown). 
Figure 2 shows, first, that criteria for testing mediation were met, and second, that higher level of 
maternal antenatal inflammation partially mediated the effect of any prenatal environmental 
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adversity on the number of areas of child neurodevelopmental delay (the effect size proportion 
mediated=55.2%, 95% CI 18.7-95.5). 
Sensitivity analyses  
Supplemental Table 5 shows that the exclusion of women diagnosed for the first time with any 
mood or anxiety disorder after childbirth, the exclusion of women with acute infections, herpes 
simplex, rheumatoid arthritis, asthma or anemia or restricting the analyses to child HILMO 
diagnoses only did not substantially change the associations.  
Discussion 
In this prospective study, higher levels of maternal antenatal hsCRP and glycoprotein acetyls were 
associated with higher number of child neurodevelopmental delay areas in a follow-up to 10.8 
years. The number of neurodevelopmental delay areas was the highest in children of women whose 
inflammation levels of both of these inflammatory biomarkers and across the three consecutive 
antenatal sampling points were the highest. Of note is that while the levels of hsCRP and 
glycoprotein acetyls are increased during pregnancy(40), which was also observed  in our sample, 
we did not observe fluctuations in the women’s inflammatory response. Instead, inflammation 
showed a high degree of stability. Associations between maternal antenatal inflammation and the 
number of neurodevelopmental delay areas were similar in girls and boys and not driven by acute 
infections or other proinflammatory conditions, as the associations did not substantially change 
when we excluded women who had an acute infection within a month of the blood sampling, 
women with herpes simplex, rheumatoid arthritis, asthma or anemia during pregnancy. Hence, our 
findings show that persistently high levels of maternal antenatal inflammation may be critical for in 
utero neurodevelopment.  
Our findings also suggest that persistently high levels of antenatal inflammation partially mediated 
the link between exposure to any prenatal environmental adversity, namely to maternal 
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overweight/obesity, diabetes, hypertensive, mood and anxiety disorders, and child 
neurodevelopmental delay. Having any of these adversities was associated with an over 2-fold 
increased risk of higher number of areas of child neurodevelopmental delay and was also 
significantly associated with persistently high levels of antenatal inflammation. The mediation 
finding suggests that maternal antenatal inflammation may provide a target for therapeutic 
interventions preventing the child from deviations from his/her optimal neurodevelopmental 
trajectory, such as dietary interventions employing vitamin D, probiotics and polyunsaturated fatty 
acids(61-64). They have been shown to be associated with reduced inflammation and they may also 
provide neurodevelopmental benefits for the fetus and mental health benefits for the pregnant 
women(65-70).   
Our findings are in line with most of the previous studies(14-18, 20) showing associations of 
maternal antenatal inflammation with impaired neurodevelopment, cognition, ASD and altered 
brain structural and functional connectivity and development in children. These studies have, 
however, been based on small sample sizes and relied mostly on a single blood sample for the 
measurement of inflammatory biomarkers at gestational stages varying across the studies. However, 
the current and previous studies are not directly comparable, as the studied set of inflammatory 
biomarkers differs. Many of the previous studies have used very rapidly degrading inflammatory 
markers, most commonly IL-6, which we lacked in this study. Instead, we focused on hsCRP, 
which is an acute-phase protein with a longer half-life than IL-6(71) and on glycoprotein acetyls 
which shows even slower kinetics than hsCRP and which has not been studied before in this 
context. These biomarkers allowed a stable estimation of the participants’ inflammatory state across 
pregnancy(39), and as they increase in response to pregnancy(40), they capture antenatal 
inflammation. In our study, glycoprotein acetyls also improved the prediction of child 
neurodevelopmental delay over hsCRP alone, suggesting that child neurodevelopmental delay may 
be best predicted by their combination. Whether the prediction could be further improved by 
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including into our model other inflammatory and related biomarkers, such as maternal steroid 
hormones, which we concurrently do not have, and which is a study limitation, warrants further 
study. Our outcome, representing an aggregate measure of neurodevelopmental delay to indicate 
deviation from typical neurodevelopmental trajectory rather than capturing specific 
neurodevelopmental deficiencies, has not been studied previously either. Shifts and/or disruptions 
from the typical neurodevelopmental trajectory in childhood often precede later development of 
severe mental disorders(72-75), suggesting that the outcomes may lie on a same continuum of 
neurodevelopmental adversities. 
Our results are in agreement with the evidence from studies examining neurodevelopmental 
outcomes in relation to maternal antenatal infection(76-78). Interestingly, a recent study among 
1,791,520 Swedish children found that fetal exposure to maternal infection increased the risk for 
ASD in the offspring, but did not find differences between severity of infection and the risk of 
ASD(76), suggesting that this is not a dose-response relationship, but that the presence of infection 
per se may play a role in neurodevelopmental programming. 
Molecular and cellular mechanisms that may underlie the neurodevelopmental programming of the 
offspring brain remain elusive(79). Animal studies have shown that maternal inflammation 
increases microglial density and/or activation in the fetal brain(79), driving these cells from 
physiological to more pathological roles, both short-term and persistently(80); in humans aberrant 
microglia have been identified postmortem in schizophrenia, depression, Tourette syndrome, and 
ASD(81). Also, animal studies have shown that exposure to maternal inflammation may result in 
over- and undergrowth of brain volume, both changes associated with ASD and schizophrenia(79). 
Alterations in synapse formation and dendritic development are core aspects of psychiatric 
pathophysiology that may mechanistically link prenatal inflammation to psychiatric risk. Animal 
studies have shown that prenatal exposure to maternal inflammation persistently reduced cortical 
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dendritic spine density, turnover, and connectivity, as well as altered excitatory and inhibitory 
synaptic transmission(82).  
Our study limitation is that 75.4% of our study participants were recruited based on their high risk 
factor status for pre-eclampsia and IUGR, which may have contributed to the relatively high 
comorbidity of prenatal environmental adversities in our sample. This limits the generalizability of 
our findings to general populations of pregnant women and hinders studying the unique effects of 
any individual environmental adversity. The high risk is, however, also a strength of our study. It 
resulted in a high prevalence of prenatal environmental adversities in our sample, providing 
increased statistical power to examine the effects of inflammation and the mediation of prenatal 
environmental adversities via inflammation on child neurodevelopment. Another strength of our 
study includes the prospective study design, availability of data from the MBR, HILMO and 
medical records which resulted in nearly null follow-up attrition. Attrition was, however, notable 
with regard to mother-reported child neurodevelopmental delay. As a result, we may have missed 
detecting children with milder delays in neurodevelopment. We believe that missing such cases may 
have rather decreased than increased our ability to detect significant associations. Finally, 
measuring maternal inflammation at three antenatal time points may still not be sufficient enough to 
capture short-lived fluctuations in antenatal inflammation.  
In conclusion, our study showed that persistently high levels of maternal antenatal inflammation, 
across three antenatal sampling points, were associated with, and mediated the effects of prenatal 
environmental adversities on the number of areas of child neurodevelopmental delay. Our findings 
provide support for the hypothesis that maternal inflammation may represent one mechanism 
underlying the neurodevelopmental programming of offspring brain. 
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Figure legends 
Figure 1. Box plots with medians (horizontal lines within boxes), interquartile ranges (error bars) 
and means (diamonds) of high sensitivity C-reactive protein (Panel A) and glycoprotein acetyls 
(Panel B)  within the three subgroups of women with low, moderate and high level of inflammation 
at three consecutive antenatal blood sampling points. The three subgroups were identified as the 
most optimal solution by the Latent Class Analysis (LCA). 
Figure 2. Mediation analysis showing that the effect of prenatal environmental adversity 
(overweight / obesity, diabetes, hypertensive disorders, mood or anxiety disorders: 0=no adversity, 
1=any adversity) on the number of child neurodevelopmental delay areas across cognitive, motor 
and social skills (0=no delay in any area, 1=one delay in any area, 2=two delays in any area, 
3=delay in all three areas) in a follow-up of 10.8 years is partially mediated via maternal 
inflammation (low, moderate and high level of high-sensitivity C-reactive protein and glycoprotein 
acetyls across the three timepoints during pregnancy identified by the latent class analysis) during 
pregnancy. Numbers above dashed lines show bi-variate associations between the variables, and 
those above solid lines results from the mediation analysis. 
Supplemental Figure 1. Agreement between the any neurodevelopmental delay identified by the 
mother-reported Ages and Stages Questionnaire (ASQ) (≤-2SD for age on any ASQ domain) and 
any psychological development disorder diagnoses (International Classification of Disease Tenth 
Revision diagnostic codes F80-F84) identified by the Care Register for Health Care (HILMO) in the 
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clinical subsample (n=502) and the analytic sample of the current study (Panel B). AC1 refers to 
chance-corrected first-order agreement coefficient and 95% CI to 95% Confidence Interval.  
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Table 1. Characteristics of the sample (418 mother-child dyads) 
 Mean (SD) / N (%) Range 
Maternal characteristics   
Age at delivery (years) 32.6 (5.2) 19.0-47.4 
   < 40 years at delivery 375 (89.7%)  
   ≥ 40 years at delivery, 43 (10.3%)  
   Missing 0  
Education   
    Lower secondary or lower 201 (48.1%)  
    Upper secondary or tertiary 211 (50.5%)  
    Missing 6 (1.4%)  
Occupational status   
   Manual laborer  68 (16.3%)  
   Junior or senior clerical 85 (20.3%)  
   Entrepreneur 87 (20.8%)  
   Other or missing 178 (42.6%)  
Body Mass Index in early pregnancy(kg/m2) 27.0 (6.5) 17.6-55.0 
   Normal weight (<24.99 kg/m2) 209 (50.0%)  
   Overweight (25-29.99 kg/m2) 86 (20.6%)  
   Obese (≥30 kg/m2) 123 (29.4%)  
   Missing 0  
Hypertensive disorders   
    Normotension 266 (63.6%)  
    Gestational hypertension  38 (9.1%)  
    Pre-eclampsia 43 (10.3%)  
    Chronic hypertension 71 (17.0%)  
    Missing 0  
Diabetes disorders   
    No 317 (75.8%)  
    Gestational diabetes 92 (22.0%)  
    Type 1 diabetes 9 (2.1%)  
    Missing 0  
Any mood disorder diagnosed before delivery (F3)*   
    No 398 (95.2%)  
    Yes 20 (4.8%)  
Any anxiety/neurotic disorder diagnosed before delivery (F4)*   
    No 400 (95.7%)  
    Yes 18 (4.3%)  
Any prenatal environmental adversity    
    No 135 (32.3%)  
    Yes 283 (67.7%)  
    Missing 0  
High-sensitivity C-reactive protein (mg/L)   
   First blood sampling point (11.1-15.1  gestational weeks) 3.81 (5.16) 0.23-32.70 
   Missing 10 (2.4%)  
   Second blood sampling point (17.1-22.9 gestational weeks) 4.53 (6.27) 0.31-60.65 
   Missing 15 (3.6%)  
   Third blood sampling point (25.3-30.6 gestational weeks) 3.95 (4.80) 0.19-61.07 
   Missing 18 (4.3%)  
 
 
 
Glycoprotein acetyls  (mmol/L)   
   First blood sampling point (11.1-15.1  gestational weeks) 1.26 (0.16) 0.89-1.85 
   Missing 21 (5.0%)  
   Second blood sampling point (17.1-22.9 gestational weeks) 1.35 (0.18) 0.94-2.14 
   Missing 20 (4.8%)  
   Third blood sampling point (25.3-30.6 gestational weeks) 1.45 (0.18) 1.06-2.25 
   Missing 29 (6.9%)  
Child characteristics   
Sex   
   Boy 223 (53.4%)  
   Girl 195 (46.7%)  
   Missing 0  
Year of birth   
   2006 69 (16.5%)  
   2007  99 (23.7%)  
   2008 112 (26.8%)  
   2009 138 (33.0%)  
   Missing 0  
Disorders of psychological development (F8)* 33 (7.9%)  
   Speech and language development (F80)* 20 (4.8%)  
   Scholastic skills (F81)* 3 (0.7%)  
   Motor development (F82)* 13 (3.1%)  
   Mixed specific developmental disorders (F83)* 7 (1.7%)  
   Autism spectrum disorder (F84)* 4 (1.0%)  
   Missing 0  
Delay in achieving developmental milestone appropriate the child’s age 
in the Ages and Stages Questionnaire (ASQ) 
  
   Communication skills (≤ -2SD) 6 (1.4%)  
   Fine motor skills (≤ -2SD)   8 (1.9%)  
   Gross motor skills (≤ -2SD) 8 (1.9%)  
   Problem solving skills (≤ -2SD) 8 (1.9%)  
   Personal social skills (≤ -2SD) 8 (1.9%)  
   Missing 223 (53.3%)  
Neurodevelopmental delay in the three broad areas   
      Cognitive development (F80, F81, F83 or ≤ -2SD  
      ASQ communication or problem solving skills)* 
34 (8.1%)  
      Motor development (F82 or ≤ -2SD ASQ fine or gross motor skills)* 25 (6.0%)  
      Social development (F84 or ≤ -2SD ASQ personal social skills)*   12 (2.9%)  
      Missing 0  
Number of neurodevelopmental delay across the three broad areas    
   Delay in any of the areas 29 (6.9%)  
   Delay in any two of the areas 15 (3.6%)  
   Delay in all three areas 4 (1.0%)  
   No delay in any area 370 (88.5%)  
   Missing 0  
*International Classification of Diseases Tenth revision diagnostic codes 
 
 
Table 2. Associations between maternal antenatal levels of high-sensitivity C-Reactive Protein and Glycoprotein acetyls and the 
number of areas of child neurodevelopmental delay across cognitive, motor and social development in a follow-up of up to 10.8 
years 
  Number of  areas of neurodevelopmental delay (0=no delay in any 
area, 1=one delay in any area, 2=two delays in any areas, 3=delay in all 
three areas) 
Relative Risk 95% Confidence Interval P 
High-sensitive C-Reactive Protein, SD units 
First blood sampling (11.1-16.7 gestational weeks) 
Model 1 1.50 1.16, 1.93 0.002 
Model 2 1.56 1.19, 2.03 0.001 
Model 3 1.41 1.07, 1.87 0.01 
Second blood sampling (17.1-22.9 gestational weeks) 
Model 1 1.45 1.13, 1.86 0.004 
Model 2 1.45 1.12, 1.87 0.005 
Model 3 1.33 1.01, 1.75 0.04 
Third blood sampling (25.3-31.1 gestational weeks) 
Model 1 1.72 1.34, 2.21 <0.0001 
Model 2 1.76 1.36, 2.28 <0.0001 
Model 3 1.64 1.25, 2.16 0.0004 
Glycoprotein acetyls, SD units  
First blood sampling (11.1-16.7 gestational weeks)  
Model 1 1.36 1.08, 1.72 0.009 
Model 2 1.42 1.10, 1.83 0.007 
Model 3 1.26 0.96, 1.66 0.09 
Second blood sampling (17.1-22.9 gestational weeks)  
Model 1 1.30 1.05, 1.61 0.02 
Model 2 1.25 1.00, 1.58 0.05 
Model 3 1.15 0.90, 1.47 0.26 
Third blood sampling (25.3-31.1 gestational weeks)  
Model 1 1.46 1.17, 1.81 0.0006 
Model 2 1.50 1.19, 1.88 0.0006 
Model 3 1.39 1.09, 1.79 0.009 
Note. Model 1 is adjusted for child sex and birth year, Model 2 is additionally adjusted for maternal age at delivery, education, 
occupation and smoking and alcohol use during pregnancy, Model 3 is additionally adjusted for prenatal adversity (maternal 
overweight/obesity, diabetes and hypertensive, mood and anxiety disorders). 
 
 
 
Supplemental Table 1. Comorbidity of prenatal environmental adversities in women with any prenatal environmental adversity. 
Number of prenatal 
environmental 
adversities 
Overweight/Obesity Hypertensive disorders Diabetes disorders Mood disorders Anxiety disorders 
Number of women 
with any prenatal 
environmental 
adversity 
One prenatal  
environmental adversity 126 
 X     64 
  X    37 
   X   21 
    X  1 
     X 3 
Two prenatal  
environmental adversities 107 
 X X    64 
 X  X   27 
 X   X  3 
 X    X 1 
  X X   7 
  X   X 2 
   X X  1 
    X X 2 
Three prenatal  
environmental adversities 42 
 X X X   36 
 X  X X  2 
 X   X X 4 
Four prenatal  
environmental adversities 6 
 X X X X  2 
 X X X  X 1 
 X  X X X 2 
 X X  X X 1 
Five prenatal  
environmental adversities 2 
 X X X X X 2 
Total 209 152 101 20 18 283 
 
Supplemental Table 2. Associations between maternal antenatal levels of high-sensitivity C-Reactive Protein and glycoprotein acetyls and 
specific neurodevelopmental delay areas. 
  
Cognitive delay 
 
Motor delay 
 
Social delay 
Odds 
Ratio 
95% 
Confidence 
Interval 
P Odds 
Ratio 
95% 
Confidence 
Interval 
P Odds 
Ratio 
95% 
Confidence 
Interval 
P 
High-sensitivity C-Reactive Protein, SD units 
First blood sampling (11.1-16.7 gestational weeks) 
Model 1 1.35 0.92, 1.98 0.13 1.64 1.05, 2.58 0.03 2.08 1.07, 4.04 0.03 
Model 2 1.31 0.87, 1.96 0.20 1.81 1.11, 2.94 0.02 2.35 1.17, 4.72 0.02 
Model 3 1.14 0.74, 1.76 0.54 1.63 0.98, 2.70 0.06 2.23 1.08, 4.59 0.03 
Second blood sampling  (17.1-22.9 gestational weeks) 
Model 1 1.23 0.84, 1.80 0.30 1.88 1.20, 2.96 0.006 1.60 0.88, 2.93 0.13 
Model 2 1.15 0.77, 1.72 0.50 2.01 1.25, 3.22 0.004 1.75 0.94, 3.27 0.08 
Model 3 1.00 0.65, 1.55 0.99 1.88 1.14, 3.11 0.01 1.65 0.85, 3.20 0.14 
Third blood sampling (25.3-31.1 gestational weeks) 
Model 1 1.68 1.12, 2.50 0.01 1.86 1.17, 2.95 0.008 2.20 1.17, 4.14 0.01 
Model 2 1.64 1.08, 2.48 0.02 1.93 1.20, 3.11 0.007 2.27 1.20, 4.28 0.01 
Model 3 1.52 0.98, 2.37 0.06 1.73 1.05, 2.85 0.03 2.16 1.08, 4.31 0.03 
Glycoprotein acetyls, SD units 
First blood sampling (11.1-16.7 gestational weeks) 
Model 1 1.28 0.88, 1.84 0.19 1.69 1.13, 2.53 0.01 1.24 0.68, 2.25 0.48 
Model 2 1.25 0.85, 1.85 0.25 1.79 1.17, 2.74 0.008 1.30 0.70, 2.42 0.41 
Model 3 1.09 0.72, 1.66 0.68 1.62 1.03, 2.54 0.04 1.15 0.58, 2.25 0.69 
Second blood sampling  (17.1-22.9 gestational weeks) 
Model 1 1.18 0.82, 1.68 0.38 1.65 1.14, 2.38 0.008 1.17 0.67, 2.07 0.58 
Model 2 1.09 0.75, 1.58 0.65 1.64 1.12, 2.40 0.01 1.21 0.68, 2.18 0.52 
Model 3 0.96 0.64, 1.44 0.84 1.53 1.02, 2.28 0.04 1.10 0.59, 2.07 0.76 
Third blood sampling (25.3-31.1 gestational weeks) 
Model 1 1.54 1.08, 2.19 0.02 1.72 1.17, 2.54 0.006 1.20 0.67, 2.17 0.54 
Model 2 1.52 1.06, 2.18 0.02 1.76 1.18, 2.63 0.006 1.23 0.69, 2.19 0.49 
Model 3 1.44 0.97, 2.14 0.05 1.61 1.05, 2.49 0.03 1.07 0.56, 2.04 0.84 
Note. Model 1 is adjusted for child sex and birth year, Model 2 is additionally adjusted for maternal age at delivery, education, occupation 
and smoking and alcohol use during pregnancy, Model 3 is additionally adjusted for prenatal adversity (maternal overweight/obesity, 
diabetes and hypertensive, mood and anxiety disorders). 
 
 
 
Supplemental Table 3. Criteria used in Latent Class Analyses for identifying the most optimal solution to group 
women based on their high-sensitivity C-reactive protein and glycoprotein acetyls at three consecutive antenatal blood 
sampling points.  
Criteria: Number of groups based on the Latent Class Analyses 2 3 4 5 6 
Goodness-of-fit      
   Akaike 
Information 
Criterion 
5936.75 5717.44 5593.29 5530.94 5458.79 
  Bayesian 
Information 
Criterion 
6013.43 5822.67 5726.46 5692.36 5648.46 
Number (%) of 
participants in 
groups 
     
   1 217 (51.9%) 71 (17.0%) 65 (15.6%) 67 (16.0%) 2 (0.5%) 
   2 201 (48.1%) 181 (43.3%) 173 (41.4%) 159 (38.0%) 112 (28.1%) 
   3  166 (39.7%) 144 (34.5%) 86 (20.6%) 111 (27.9%) 
   4   36 (8.6%) 28 (6.7%) 80 (20.1%) 
   5    78 (18.7%) 25 (6.3%) 
   6     68 (17.1%) 
Certainty of 
classification by 
posterior 
probability 
0.96 
(SD 0.10) 
0.93 
(SD 0.12) 
0.91 
(SD 0.12) 
0.88 
(SD 0.15) 
0.86 
(SD 0.15) 
Clinical relevance Clearly defined 
groups with 
consistently low 
and consistently 
high 
inflammation. 
 
Clearly defined 
groups with 
consistently 
low, 
consistently 
moderate and 
consistently 
high 
inflammation. 
 
Clearly defined 
groups with 
consistently low 
and consistently 
moderate 
inflammation, 
two groups with 
consistently 
high 
inflammation 
are not clearly 
different  
Clearly defined 
group with 
consistently low 
inflammation,  
two groups with 
consistently 
moderate 
inflammation 
are not clearly 
different, two 
groups with 
consistently 
high 
inflammation 
are not clearly 
different  
Two groups 
with consistently 
low 
inflammation 
are not clearly 
different, two 
groups with 
consistently 
moderate 
inflammation 
are not clearly 
different, two 
groups with 
consistently high 
inflammation 
are not clearly 
different  
Clinically 
relevant. Easy 
to identify 
women at risk 
Clinically 
relevant. Easy to 
identify women 
at risk, more 
targeted 
identification of 
risk as 
compared to the 
two group 
solution 
Clinical relevance of segregating the groups that do not 
distinctly differ from each other is not clear. LCA with 
4-6 groups can be scaled down to the 3 groups solution. 
 
 
 
 
Supplemental Table 4. Criteria used in Latent Class Analyses for identifying the most optimal solution to group 
women based on their  high-sensitivity C-reactive protein at three consecutive antenatal blood sampling points.  
Criteria: Number of groups based on the Latent Class Analyses 2 3 4 5 6 
Goodness-of-fit      
   Akaike 
Information Criterion 3017.26 2834.08 2760.43 2722.72 2668.08 
   Bayesian 
Information Criterion 3057.61 2890.58 2833.07 2811.50 2773.00 
Number (%) of 
participants in 
groups 
     
   1 170 (40.7%) 56 (13.4%) 33 (7.9%) 10 (2.4%) 9 (2.2%) 
   2 248 (59.3%) 196 (46.9%) 126 (30.1%) 53 (12.7%) 54 (12.9%) 
   3  166 (39.7%) 177 (42.3%) 133 (31.82%) 129 (30.9%) 
   4   82 (19.6%) 150 (35.9%) 141 (33.7%) 
   5    72 (17.2%) 76 (18.2%) 
   6     9 (2.2%) 
Certainty of 
classification by 
posterior 
probability 
0.94 
(SD 0.12) 
0.91 
(SD 0.13) 
0.88 
(SD 0.14) 
0.87 
(SD 0.14) 
0.87 
(SD 0.14) 
Clinical relevance Clearly defined 
groups with 
consistently low 
and consistently 
high 
inflammation. 
 
Clearly defined 
groups with 
consistently 
low, 
consistently 
moderate and 
consistently 
high 
inflammation. 
 
Two groups 
with 
consistently low 
inflammation 
are not clearly 
different, clearly 
defined groups 
with 
consistently 
moderate and 
consistently 
high 
inflammation  
Three groups 
with 
consistently low 
inflammation 
are not clearly 
different, clearly 
defined groups 
with 
consistently 
moderate and 
consistently 
high 
inflammation 
Three groups 
with consistently 
low 
inflammation 
are not clearly 
different, clearly 
defined groups 
with consistently 
moderate and 
high 
inflammation, 
group 6 (n=9) 
displayed low 
inflammation at 
the first and 
third time points 
and high 
inflammation at 
the second time 
point  
Clinically 
relevant. Easy 
to identify 
women at risk 
Clinically 
relevant. Easy to 
identify women 
at risk, more 
targeted 
identification of 
risk as 
compared to the 
two group 
solution 
Clinical relevance of segregating the groups that do not 
distinctly differ from each other is not clear. LCA with 
4-6 groups can be scaled down to the 3 group solution. 
 
 
 
 
Supplemental Table 5. Sensitivity analyses of associations between maternal inflammatory biomarker subgroups identified by the 
latent class analysis (groups on low, moderate and high levels of high-sensitivity C-reactive protein and glycoprotein acetyls across 
the three consecutive antenatal timepoints) and the number of areas of child neurodevelopmental delay across cognitive, motor and 
social development in a follow-up to10.8 years 
 
 
Low, moderate and high level of maternal inflammation 
based on Latent Class Analysis 
Number of  areas of neurodevelopmental delay (0=no delay in any 
area, 1=one delay in any area, 2=two delays in any areas, 3=delay in all 
three areas) 
Relative Risk 95% Confidence 
Interval 
P 
Sensitivity analysis 1: women who were diagnosed with 
any mood or anxiety disorder after the delivery are 
excluded (n=34) 
2.18 1.40, 3.39 0.0005 
Sensitivity analysis 2: women who were diagnosed with 
acute infectious diseases, rheumatoid arthritis, asthma, 
herpes simplex are excluded (n=29) 
2.19 1.45, 3.32 0.0002 
Sensitivity analysis 3: women whose  maximum 
hemoglobin value during pregnancy was lower than 105 
g/L are excluded (n=79) 
2.17 1.35, 3.48 0.001 
Sensitivity analysis 4: mother-reported Ages and Stages 
Questionnaire data are excluded from the child’s 
developmental delay variable (n=34 mother-reported 
delays; child’s developmental delay is based only on the  
Care Register for Health Care disorder diagnosis data) 
1.97 1.07, 3.60 0.03 
Note. The models are adjusted for child sex and birth year. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
